<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163272">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02095496</url>
  </required_header>
  <id_info>
    <org_study_id>StLuc</org_study_id>
    <nct_id>NCT02095496</nct_id>
  </id_info>
  <brief_title>Efficacy of Closed-loop Ventilation to Reduced Sleep Disorders</brief_title>
  <acronym>SleepICU</acronym>
  <official_title>Contribution to the Understanding of the Involvement of Mechanical Ventilation in ICU Patients Sleep Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sleep's deficiencies are very common in intensive care. Mechanical ventilation is a known
      factor in this deterioration.The investigators hypothesize that close-loop ventilation mode
      (Intellivent-ASV) is able to minimize sleep deterioration, adjusting ventilation to the
      patient needs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In intensive care, conventional mechanical ventilation (pressure support) generates apneas
      and asynchronies during sleep. Intellivent-ASV would be able to avoid apneas, providing
      controlled cycles when respiratory rate become too low. Moreover, the constant adjustment of
      ventilatory parameters to the patient needs would avoid asynchronies between the ventilator
      and the patient ventilatory drive.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Sleep fragmentation index</measure>
    <time_frame>12 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>= number of awakenings and arousals per hour of sleep</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of sleep episodes</measure>
    <time_frame>12 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of the sleep</measure>
    <time_frame>12 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>distribution of the sleep during day and night</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Sleep's architecture</measure>
    <time_frame>12 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>proportion of the different phases of sleep (slow waves sleep stage 1, 2, 3 and 4 and Rapid Eye Movement (REM) sleep)</description>
  </other_outcome>
  <other_outcome>
    <measure>ventilation</measure>
    <time_frame>12 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>number of asynchronies and apneas and ventilatory variability</description>
  </other_outcome>
  <other_outcome>
    <measure>circadian rhythm</measure>
    <time_frame>6 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasmatic melatonin dosage</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Mechanical Ventilatory Failure</condition>
  <condition>Psychosis Associated With Intensive Care</condition>
  <arm_group>
    <arm_group_label>Intellivent-ASV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Intellivent-ASV ventilation during 12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional ventilation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive pressure support ventilation during 12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intellivent-ASV</intervention_name>
    <arm_group_label>Intellivent-ASV</arm_group_label>
    <other_name>closed-loop ventilation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conventional ventilation</intervention_name>
    <arm_group_label>Conventional ventilation</arm_group_label>
    <other_name>pressure support ventilation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient under invasive mechanical ventilation since at least 6 hours and for expected
             at least 48 hours duration, including a continuous period of 24h, from 2 p.m. to 2
             p.m. the next day.

          -  Age &gt; 18 years

          -  Body Mass Index &lt; 40

          -  informed consent signed by the family

        Exclusion Criteria:

          -  patient requiring neuo-muscular blocking agent or deep sedation enough to abolish
             spontaneous ventilatory effort

          -  patient with encephalopathy regardless of origin

          -  Patient with Glasgow coma scale score &lt; 8

          -  Patient abusing of drug or alcohol

          -  patient with a contraindication for placement of a nasogastric tube such that
             sufferers of esophageal or gastric ulcer, tumors, diverticulitis or bleeding varices
             or patients with sinusitis epistaxis or having recently been operated on the nose or
             pharynx

          -  Patient with bleeding disorders

          -  Patient with unstable respiratory situation as defined by a arterial oxygen partial
             pressure and inspired oxygen fraction ratio (PaO2/FiO2) &lt; 100 mmHg with positive end
             expiratory pressure (PEEP) &gt; 12 cmH2O

          -  Patient with unstable hemodynamic situation as defined by Systolic Blood Pressure
             (SBP) &lt; 75 mmHg despite a therapeutic optimization

          -  Inclusion in another research protocol submitted to consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>94 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilie Bialais, PhD Student</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires Saint-Luc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilie Bialais, PhD Student</last_name>
    <phone>02/764 27 18</phone>
    <phone_ext>+32</phone_ext>
    <email>emilie.bialais@uclouvain.Be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philippe Hantson, PhD</last_name>
    <phone>02/764 27 55</phone>
    <phone_ext>+35</phone_ext>
    <email>philippe.hantson@uclouvain.Be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Intensive Care Unit, Saint Luc university Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Emilie Bialais, PhD Student</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe Hantson, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier Wittebole, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 20, 2014</lastchanged_date>
  <firstreceived_date>March 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sleep</keyword>
  <keyword>intensive care</keyword>
  <keyword>mechanical ventilation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Sleep Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Hypoventilation</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
